Aardvark Therapeutics, Inc.

Contributing Author

Recent Articles by Aardvark Therapeutics, Inc.

13 hours	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek AARD -8.28% GlobeNewswire
Oct-08	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome AARD GlobeNewswire
Sep-23	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum AARD GlobeNewswire
Sep-04	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) AARD GlobeNewswire
Aug-27	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September AARD GlobeNewswire
Aug-13	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates AARD GlobeNewswire
Aug-12	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy AARD GlobeNewswire
Jul-18	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) AARD GlobeNewswire
Jun-24	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference AARD GlobeNewswire
May-19	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions AARD GlobeNewswire
May-14	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights AARD GlobeNewswire
May-07	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May AARD GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.